Oruka Therapeutics, Inc. ORKA Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount?
- Oruka Therapeutics, Inc. (ORKA) reported valuation allowance, deferred tax asset, increase (decrease), amount of $6.85M in Q4 2025.
- How has Oruka Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount changed year-over-year?
- Oruka Therapeutics, Inc.'s valuation allowance, deferred tax asset, increase (decrease), amount decreased by 67.9% year-over-year, from $21.32M to $6.85M.
- What does valuation allowance, deferred tax asset, increase (decrease), amount mean?
- This measures the absolute change in the valuation allowance established against deferred tax assets. An increase in this allowance suggests that the company is becoming less certain about its ability to utilize tax assets, often due to sustained operating losses.